Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
AUROPHARMA.NS Stock Summary
Top 10 Correlated ETFs
AUROPHARMA.NS
In the News
AUROPHARMA.NS Financial details
Company Rating
Buy
Market Cap
597.57B
Income
27.7B
Revenue
275.91B
Book val./share
-
Cash/share
-
Dividend
6
Dividend %
0.53%
Employees
23.45K
Optionable
No
Shortable
Yes
Earnings
25 May 2024
P/E
28.56
Forward P/E
16.79
PEG
62.65
P/S
2.47
P/B
2.36
P/C
-
P/FCF
-11469.12
Quick Ratio
0.93
Current Ratio
1.81
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
47.25
EPS next Y
64.85
EPS next Q
15.35
EPS this Y
-27.2%
EPS next Y
37.25%
EPS next 5Y
53.65%
EPS last 5Y
-4%
Revenue last 5Y
5.07%
Revenue Q/Q
1.69%
EPS Q/Q
25.02%
-
-
-
-
SMA20
-0.86%
SMA50
-7.53%
SMA100
19.58%
Inst Own
-
Inst Trans
-
ROA
5%
ROE
17%
ROC
0.11%
Gross Margin
54%
Oper. Margin
13%
Profit Margin
9%
Payout
-
Shs Outstand
585.94M
Shs Float
281.54M
-
-
-
-
Target Price
-
52W Range
485.0-1177.1
52W High
-7.5%
52W Low
+124.48%
RSI
59
Rel Volume
0.75
Avg Volume
2.75M
Volume
2.06M
Perf Week
6.99%
Perf Month
9.3%
Perf Quarter
20.86%
Perf Half Y
24.62%
-
-
-
-
Beta
0.581
-
-
Volatility
31.55%, 25.5%
Prev Close
1.72%
Price
1088.75
Change
3.69%
AUROPHARMA.NS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-03-31
Metric | History | 2019-03-31 | 2020-03-31 | 2021-03-31 | 2022-03-31 | 2023-03-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 328.14 | 388.06 | 419.12 | 398.79 | 420.13 | |
Net income per share | 40.36 | 48.56 | 91.05 | 45.2 | 32.9 | |
Operating cash flow per share | 27.68 | 74.77 | 56.81 | 85.61 | 40.73 | |
Free cash flow per share | 0.28 | 50.35 | 24.83 | 39.46 | -5.69 | |
Cash per share | 32.92 | 48.51 | 95.93 | 77.78 | 111.37 | |
Book value per share | 237.08 | 286.9 | 374.27 | 419.43 | 458.07 | |
Tangible book value per share | 184.07 | 231.16 | 321.01 | 357.73 | 391.34 | |
Share holders equity per share | 237.08 | 286.9 | 374.27 | 419.43 | 458.07 | |
Interest debt per share | 121.48 | 109.96 | 95.73 | 56.59 | 92.62 | |
Market cap | 464.24B | 242.08B | 516.39B | 391.73B | 303.57B | |
Enterprise value | 515.36B | 277.46B | 518.15B | 382.89B | 312.47B | |
P/E ratio | 19.63 | 8.51 | 9.68 | 14.79 | 15.75 | |
Price to sales ratio | 2.41 | 1.06 | 2.1 | 1.68 | 1.23 | |
POCF ratio | 28.62 | 5.53 | 15.51 | 7.81 | 12.72 | |
PFCF ratio | 2.79K | 8.21 | 35.49 | 16.94 | -90.99 | |
P/B Ratio | 3.34 | 1.44 | 2.35 | 1.59 | 1.13 | |
PTB ratio | 3.34 | 1.44 | 2.35 | 1.59 | 1.13 | |
EV to sales | 2.68 | 1.22 | 2.11 | 1.64 | 1.27 | |
Enterprise value over EBITDA | 12.81 | 5.64 | 9.63 | 8.29 | 7.82 | |
EV to operating cash flow | 31.77 | 6.33 | 15.57 | 7.63 | 13.09 | |
EV to free cash flow | 3.1K | 9.4 | 35.61 | 16.56 | -93.65 | |
Earnings yield | 0.05 | 0.12 | 0.1 | 0.07 | 0.06 | |
Free cash flow yield | 0 | 0.12 | 0.03 | 0.06 | -0.01 | |
Debt to equity | 0.5 | 0.37 | 0.25 | 0.13 | 0.2 | |
Debt to assets | 0.26 | 0.22 | 0.16 | 0.1 | 0.13 | |
Net debt to EBITDA | 1.27 | 0.72 | 0.03 | -0.19 | 0.22 | |
Current ratio | 1.28 | 1.44 | 1.86 | 2.22 | 1.87 | |
Interest coverage | 21.94 | 27.82 | 74.76 | 89.75 | 18.16 | |
Income quality | 0.52 | 1.17 | 0.45 | 1.49 | 0.91 | |
Dividend Yield | 0 | 0.01 | 0 | 0.01 | 0.01 | |
Payout ratio | 0.06 | 0.06 | 0.04 | 0.1 | 0.23 | |
Sales general and administrative to revenue | 0.02 | 0.03 | 0.03 | 0.03 | 0.03 | |
Research and developement to revenue | 0 | 0.01 | 0 | 0 | 0 | |
Intangibles to total assets | 0.12 | 0.11 | 0.09 | 0.11 | 0.1 | |
Capex to operating cash flow | -0.99 | -0.33 | -0.56 | -0.54 | -1.14 | |
Capex to revenue | -0.08 | -0.06 | -0.08 | -0.12 | -0.11 | |
Capex to depreciation | -2.4 | -1.48 | -1.78 | -2.4 | -2.19 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 464 | 559.86 | 875.62 | 653.08 | 582.27 | |
ROIC | 0.12 | 0.13 | 0.12 | 0.09 | 0.06 | |
Return on tangible assets | 0.1 | 0.11 | 0.17 | 0.09 | 0.05 | |
Graham Net | -43.3 | -36.44 | 17.15 | 39.75 | 20.88 | |
Working capital | 33.22B | 50.26B | 91.58B | 99.67B | 100.52B | |
Tangible asset value | 107.85B | 135.45B | 188.09B | 209.61B | 229.3B | |
Net current asset value | 28.03B | 42.97B | 78.99B | 87.75B | 85.08B | |
Invested capital | 0.5 | 0.37 | 0.25 | 0.13 | 0.2 | |
Average receivables | 53.9B | 51.75B | 40.56B | 40.92B | 45.48B | |
Average payables | 26.52B | 26.11B | 26.7B | 27.49B | 32.87B | |
Average inventory | 65.52B | 74.73B | 83.63B | 82.9B | 80.33B | |
Days sales outstanding | 113.23 | 70.38 | 55.39 | 69.61 | 68.8 | |
Days payables outstanding | 112.15 | 95.42 | 103.01 | 97.3 | 125.12 | |
Days of inventory on hand | 303.54 | 288.69 | 332.71 | 271.9 | 275.08 | |
Receivables turnover | 3.22 | 5.19 | 6.59 | 5.24 | 5.31 | |
Payables turnover | 3.25 | 3.83 | 3.54 | 3.75 | 2.92 | |
Inventory turnover | 1.2 | 1.26 | 1.1 | 1.34 | 1.33 | |
ROE | 0.17 | 0.17 | 0.24 | 0.11 | 0.07 | |
Capex per share | -27.4 | -24.42 | -31.98 | -46.16 | -46.43 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q3
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 109.02 | 108.86 | 115.89 | 122.04 | 124.57 | |
Net income per share | 8.38 | 8.64 | 9.74 | 12.92 | 16.04 | |
Operating cash flow per share | 10.97 | -0.1 | 11.15 | 25.6 | 14.5 | |
Free cash flow per share | 10.97 | -0.1 | 11.15 | 0.08 | 14.5 | |
Cash per share | 110.45 | 111.37 | 106.37 | 126.92 | 0 | |
Book value per share | 435.89 | 458.07 | 458.27 | 481.09 | 0 | |
Tangible book value per share | 0 | 391.34 | 0 | 415.75 | 0 | |
Share holders equity per share | 435.89 | 458.07 | 458.27 | 481.09 | 0 | |
Interest debt per share | 0.77 | 91.17 | 0.97 | 114.63 | 1.29 | |
Market cap | 256.82B | 303.57B | 426.18B | 535.75B | 630.51B | |
Enterprise value | 321.53B | 312.47B | 488.51B | 560.92B | 630.51B | |
P/E ratio | 13.07 | 14.99 | 18.67 | 17.69 | 16.84 | |
Price to sales ratio | 4.02 | 4.76 | 6.28 | 7.49 | 8.67 | |
POCF ratio | 39.95 | -5.28K | 65.25 | 35.71 | 74.48 | |
PFCF ratio | 39.95 | -5.28K | 65.25 | 11.35K | 74.48 | |
P/B Ratio | 1.01 | 1.13 | 1.59 | 1.9 | 0 | |
PTB ratio | 1.01 | 1.13 | 1.59 | 1.9 | 0 | |
EV to sales | 5.03 | 4.9 | 7.19 | 7.84 | 8.67 | |
Enterprise value over EBITDA | 30.73 | 27.62 | 38.62 | 35.93 | 35.8 | |
EV to operating cash flow | 50.02 | -5.43K | 74.8 | 37.39 | 74.48 | |
EV to free cash flow | 50.02 | -5.43K | 74.8 | 11.88K | 74.48 | |
Earnings yield | 0.02 | 0.02 | 0.01 | 0.01 | 0.01 | |
Free cash flow yield | 0.03 | 0 | 0.02 | 0 | 0.01 | |
Debt to equity | 0 | 0.2 | 0 | 0.24 | 0 | |
Debt to assets | 0 | 0.13 | 0 | 0.15 | 0 | |
Net debt to EBITDA | 6.18 | 0.79 | 4.93 | 1.61 | 0 | |
Current ratio | 0 | 1.87 | 0 | 1.81 | 0 | |
Interest coverage | 16.13 | 14.13 | 14.59 | 16.78 | 17.71 | |
Income quality | 1.31 | -0.01 | 1.14 | 1.98 | 0.9 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0.06 | 0.06 | 0.06 | 0.04 | 0.05 | |
Intangibles to total assets | 0 | 0.1 | 0 | 0.09 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | -1 | 0 | |
Capex to revenue | 0 | 0 | 0 | -0.21 | 0 | |
Capex to depreciation | 0 | 0 | 0 | -2.01 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 286.75 | 298.41 | 316.92 | 374 | 0 | |
ROIC | 0.02 | 0.02 | 0.02 | 0.02 | 0 | |
Return on tangible assets | 0 | 0.01 | 0 | 0.02 | 0 | |
Graham Net | 110.45 | 20.88 | 106.37 | -2.42 | 0 | |
Working capital | 64.72B | 100.52B | 62.33B | 105.43B | 0 | |
Tangible asset value | 0 | 229.3B | 0 | 243.6B | 0 | |
Net current asset value | 64.72B | 85.08B | 62.33B | 78.26B | 0 | |
Invested capital | 0 | 0.2 | 0 | 0.24 | 0 | |
Average receivables | 20.16B | 23.2B | 23.2B | 23.39B | 23.39B | |
Average payables | 17.58B | 19.36B | 19.36B | 22.53B | 22.53B | |
Average inventory | 39.45B | 42.56B | 42.56B | 46.41B | 46.41B | |
Days sales outstanding | 0 | 65.47 | 0 | 58.88 | 0 | |
Days payables outstanding | 0 | 118.87 | 0 | 125.28 | 0 | |
Days of inventory on hand | 0 | 261.35 | 0 | 258.1 | 0 | |
Receivables turnover | 0 | 1.37 | 0 | 1.53 | 0 | |
Payables turnover | 0 | 0.76 | 0 | 0.72 | 0 | |
Inventory turnover | 0 | 0.34 | 0 | 0.35 | 0 | |
ROE | 0.02 | 0.02 | 0.02 | 0.03 | 0 | |
Capex per share | 0 | 0 | 0 | -25.52 | 0 |
AUROPHARMA.NS Frequently Asked Questions
What is Aurobindo Pharma Limited stock symbol ?
Aurobindo Pharma Limited is a IN stock and trading under the symbol AUROPHARMA.NS
What is Aurobindo Pharma Limited stock quote today ?
Aurobindo Pharma Limited stock price is $1088.75 today.
Is Aurobindo Pharma Limited stock public?
Yes, Aurobindo Pharma Limited is a publicly traded company.